This combination showed potential for improving the efficacy of gefitinib in EGFR-mutant NSCLC and suggested the potential benefit of vorinostat for improving the efficacy of EGFR-TKIs in these patients [262]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.